‘Everybody’s talking about it’: Metsera bidding war grips the obesity fieldnews2025-11-05T10:00:02+00:00November 5th, 2025|Endpoints News|
Arena BioWorks shuts down after investors pull plug on bid to reinvent biotechnews2025-11-04T23:25:15+00:00November 4th, 2025|Endpoints News|
Madrigal CEO welcomes MASH competition from Novo as demand climbs higher for Rezdiffranews2025-11-04T20:25:52+00:00November 4th, 2025|Endpoints News|
What health tech stands to gain as pharma goes DTCnews2025-11-04T16:50:05+00:00November 4th, 2025|Endpoints News|
Incyte, Prelude ink rare blood cancer pact; Merck takes back rights to Prometheus assetnews2025-11-04T15:31:15+00:00November 4th, 2025|Endpoints News|
Lilly and Novo near White House deal on obesity drug pricesnews2025-11-04T15:19:45+00:00November 4th, 2025|Endpoints News|
Updated: Novo ups Metsera bid to as much as $10B in attempt to top Pfizer’s new offernews2025-11-04T14:44:43+00:00November 4th, 2025|Endpoints News|
GoodRx wants in on TrumpRx as it grows its work with manufacturersnews2025-11-04T14:00:47+00:00November 4th, 2025|Endpoints News|
Jennifer Doudna startup Azalea Therapeutics launches with $82Mnews2025-11-04T13:00:49+00:00November 4th, 2025|Endpoints News|
As pharma pour billions in US manufacturing, CDMOs see future opportunitiesnews2025-11-04T13:00:34+00:00November 4th, 2025|Endpoints News|
